Why the study?
Antiarrhythmic therapy has lagged other areas of cardiology, potentially due to a lack of organization of recent electrophysiological and biomolecular findings into a coherent hypothesis relating fundamental physiological mechanisms to clinical therapy.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Introduces two-clock model of arrhythmogenesis; extends Vaughan Williams framework for targeted antiarrhythmic research and therapy.
Around 3.7 million individuals worldwide die each year from cardiac arrhythmias; this exceeds the total numbers of deaths from all cancers in the Western world.1 Despite major progress in interventional including device therapy, antiarrhythmic medication remains central to their management. In the late 1960s, Miles Vaughan Williams2,3 classified the existing drugs then used to treat cardiac arrhythmias. This was widely adopted worldwide in both clinical management and as guidance for the development of new drugs that have saved countless lives. However, the subsequent 50 years witnessed a heightened understanding of arrhythmic mechanisms and their biomolecular basis.4,5 This was accompanied by discovery of the considerable number of their underlying membrane ion channel and intracellular ion transport regulatory protein molecules and characterization of their precise roles in normal and arrhythmic activity.6 Emerging evidence over the last two decades strongly suggests that this normal electrical function of the heart is the result of dynamic and orchestrated interactions between membrane ion channels and intracellular ion transport regulatory protein molecules within a complex molecular network.7 These insights both enhanced our understanding of the pharmacological mechanism of actions of existing drugs and offered novel physiological targets for drug development. Yet, clinical practice may not have optimally benefitted from these advances. Arrhythmias remain a major clinical problem. Their therapy has often lagged progress in many other areas of cardiological medicine. Might such a lack of progress reflect a lack of clarity or of organization of these more recent and myriad findings into a coherent hypothesis that might relate fundamental physiological mechanisms to clinical therapy? Thus the Vaughan-Williams scheme had embedded such a simplified yet pragmatic working model for cardiomyocyte function in terms of then established drugs. It regarded arrhythmia as a consequence of a disruption of normal cardiac electrophysiological activation. This primarily invoked normal and abnormal function in surface membrane ion channels. It then organized these fundamental physiological mechanisms into a simple system effectively constituting what might be termed a surface membrane (M) clock (cf8). Individual drugs were identified with then known ion channels and their possible actions on these activation and recovery processes. Such cyclically operating systems are exemplified elsewhere by the circadian rhythms ubiquitous in biological systems, in which misalignments produce negative functional effects. Although possibly oversimplified the Vaughan-Williams scheme had provided a coherent framework for diagnostic analysis and therapeutic action, often thereby directly facilitating clinical management.9 Any over-simplification of the actual physiological or clinical situation was mitigated by the advantages offered by its clarity and simplicity, as well as its explicit and legitimate correlations of particular therapies with then known arrhythmic targets (referenced in Lei et al.7). It has thus remained the most clinically useful and pedagogically popular classification of anti-arrhythmic drugs (AAD). Furthermore, the few subsequent attempts to clarify these links between mechanisms of actions and therapeutic effects, exemplified by the important publication from a Working Group of the European Society of Cardiology in 1991 achieved limited success.10 We speculate that our recent modernized Oxford classification7 and its future developments may offer a pragmatic successor. It seeks to capture the greater proportion of both currently employed and the more recently discovered therapeutic and investigational agents. Its classification maps directly onto the recent, important and extensive, insights and developments in cardiac electrophysiology and pharmacology. The latter have now often succeeded in identifying particular arrhythmic phenotypes with abnormalities in particular ion channels, ion transporters and signalling agents that might offer real or potential therapeutic targets at the molecular level. Embedded within it is an updated model for normal and abnormal cardiac electrophysiological activity that relates directly to its suggested classes of drug targets and their established and potential therapeutic effects (Figure 1). Thus, it added to the original M-clock, a further oscillator reflecting intracellular events contributing to cardiac activity. Many of these bear on Ca2+ homeostasis11 and thus thereby come together into an additional, ‘Ca2+ (C)-clock’. Normal cardiac excitation then requires the cyclic events in the two clocks to be aligned. Disruption in this alignment leads to arrhythmia. These cycles in turn function within a broader envelop of diurnal variations in protein expression and function, and metabolic activity, driven by self-sustained cardiac circadian clock mechanisms.12 Molecular ion channel and transporter, and signalling components contributing to normal cardiac activity and arrhythmic events and their grouping (AADs 0-VII) into pharmacological targets in the updated Oxford classification scheme.7 This scheme maps onto a two-clock scheme for normal and abnormal cardiac electrophysiological function. A membrane (M) clock mediates surface electrophysiological changes and conduction of excitation but feeds forwards onto the calcium (C-) clock through producing alterations in cytosolic Ca2+. These trigger cycles of store Ca2+ release and re-uptake normally driven by activation and recovery processes in the M-clock. However, the C-clock also feeds back onto the M-clock, altering AP conduction, recovery, and post-recovery stability, besides exerting longer-term effects on channel expression. Autonomic sympathetic and parasympathetic control mechanisms act at different control points respectively situated in the C- and M-clocks. cAMP, cyclic 3′5-adenosine monophosphate; Cx, connexin; Gi, inhibitory G protein; Gs, stimulatory G-protein; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; MSC, mechanically sensitive channel; PKA, protein kinase A; PLB, phospholamban; RyR2, cardiac ryanodine receptor, type 2; SERCA, sarcoplasmic reticulum Ca2+-ATPase; Na+, K+ and Ca2+ flux through Nav1.5, Kv and Ca1.2 channels also shown. Table 1 derives a simplification of the modernized Oxford classification7 directed at drugs in current clinical use as opposed to investigational agents. It reflects its organization in retaining but extending the original Vaughan Williams classes I–IV bearing respectively on action potential (AP) activation, autonomic action, AP recovery, and Ca2+ current, respectively. It expands these classes in the light of recent advances. Thus, inclusion in class I of late Na+ current provides a basis for potential therapeutic manoeuvres targeted at differential regulation of Na+ channel subtypes. This has evoked recent interest in relationship to arrhythmogenesis in failing human myocardium.13 It then adds class 0, V, VI, VII agents modifying sino-atrial automaticity, mechanosensitive and connexin associated channels, as well as upstream modulatory targets. Thus, it first incorporates the original sequential cycles of surface membrane voltage-gated Na+ channel-mediated AP depolarization, and refractoriness, and K+ channel-mediated repolarization paced by SAN activity. However, this membrane (M-) clock is also linked to tissue level intercellular as opposed to intracellular processes that also affect AP conduction. Pro-arrhythmic AP conduction slowing thus can follow both reduced inward Na+ current compromising AP activation or anatomical changes altering connexin (Cx)-dependent intercellular conductances, thereby causing functionally or anatomically defined re-entrant pathways.9 A modernized classification of current antiarrrhythmic drugs (based on Lei et al.7) AF, atrial fibrillation; Af, atrial flutter; AT, atrial tachycardia; AV, atrioventricular; AVN, atrioventricular node; cAMP, cyclic 3′,5′-adenosine monophosphate; CPVT, catecholaminergic polymorphic ventricular tachycardia; HR, heart rate; PVC, premature ventricular contraction; SQTS, short QT syndrome; VF, ventricular fibrillation; VT, ventricular tachycardia; WPW, Wolf–Parkinson–White syndrome. Of categories in the full classification of (Lei et al.7), Classes V (mechanosensitive channel blockers), VI (gap junction channel blockers) and subclasses IIIc (transmitter dependent K+ channel blockers), IVc (sarcoplasmic reticular Ca2+-ATPase activators), IVd (surface membrane ion exchange inhibitors) and IVe (phosphokinase and phosphorylase inhibitors) include investigational but not clinically approved drugs and are not listed here. Class VII (upstream target modulators) contains approved drugs not in current direct use for antiarrhythmic therapy. Second, it also incorporates the depolarization-induced activation of L-type Ca2+ channels that produces the AP plateau. The latter activation events are also strategic in that they feed-forward to the C-clock whose operation is thus normally synchronously initiated and terminated by events associated with corresponding activation and recovery events in the M-clock. Thus the resulting Ca2+ influx triggers ryanodine (RyR2) or inositol trisphosphate receptor-mediated SR Ca2+ release elevating cytosolic [Ca2+]. This is terminated and reversed with repolarization. Ca2+-ATPase mediated Ca2+ re-uptake into the SR or Na+-Ca2+ exchanger mediated expulsion into the extracellular space then restores resting cytosolic [Ca2+] completing its duty cycle.11 The resulting scheme thus systematically classifies the entire repertoire of molecules potentially implicated in pro-arrhythmic conditions, variations in which may contribute variability to anti-arrhythmic drug actions. It may thus facilitate more targeted in silico and stem cell developments towards efficacious personalized therapies allowing for such variation particularly in complex conditions such as atrial fibrillation.14 Arrhythmias directly result from abnormal automaticity originating from specialized conducting SAN, atrioventricular node or Purkinje fibres, or pathological generation or conduction of excitation by atrial and ventricular cardiomyocytes, involving the M-clock. However, particular intracellular events forming the resulting intracellular C-clock feed-back onto specific M-clock components, with potential pro-arrhythmic consequences. Altered Ca2+ channel function itself may underly pro-arrhythmic, triggering, early after-depolarization phenomena during late phase 2 or early phase 3 often of prolonged APs in common with increased late Na+ or decreased K+ current contributions to prolonged electrocardiographic QT intervals, resulting in electrophysiological events misaligned with and thus disturbing M-clock function. Elevated sarcoplasmic [Ca2+] arising from Ca2+ or mechanosensitive channel activity, or increased RyR2 Ca2+ sensitivity, can trigger propagating waves of spontaneous SR Ca2+ release thus decoupling M- and C-clock activity. Thus the resulting increased cytosolic [Ca2+] may transiently increase electrogenic Na+/Ca2+ exchange current driving delayed after-depolarizations following full AP repolarization.11 It may also downregulate longer-term Na+ channel expression and function compromising conduction. The inward depolarizing nature of Na+/Ca2+ exchange also may contribute to SAN automaticity.8 Finally, the coloured annotations match the targets identified in Figure 1 to the specific anti-arrhythmic drug classes enumerated by the modernized Oxford scheme.7 This thus matches therapeutic strategies for antiarrhythmic treatment to specific components of the model. We thus emerge with a new relatively simple guidance scheme relating arrhythmic mechanisms to treatment strategies. We hope this will facilitate more effective use of what is now available whilst encouraging therapeutic advance. Conflict of interest: none declared. Our work is supported by the Medical Research Council (MR/M001288/1, CLHH, G10002647, G1002082, ML), the Wellcome Trust (105727/Z/14/Z), British Heart Foundation (BHF) (PG/14/79/31102, and PG/15/12/31280: CLHH; PG/14/80/31106, PG/16/67/32340, PG/12/21/29473, PG/11/59/29004: ML) and BHF Centres for Research Excellence (CRE) at Cambridge (CLHH) and Oxford (ML) and a Chinese Nature Science Foundation Grant (31171085: ML). Biography: Professor Ming Lei FRSB is Reader in Cardiac Pharmacology at the University of Oxford. Following clinical cardiological and physiological training at Tongji Medical University, Wuhan, China, he completed his DPhil at the University of Oxford. His cardiological contributions fall within the area of understanding cardiac ion channel function and its regulation under both physiological and pathological conditions. He has made extensive contributions towards demonstrating and characterizing the novel roles of a multifunctional enzyme, p21 activated kinase and its central role in regulating cardiac excitation. He has identified this as a critical signalling hub in cardioprotection, and a novel therapeutic target in the management of cardiac disease conditions including cardiac arrhythmias. He serves as a Senior Editor for Experimental Physiology and for Journal of Molecular and Cellular Cardiology. Biography: Christopher L.-H. Huang FESC is Professor of Cell Physiology in the University of Cambridge. He read Physiology and Clinical Medicine at the Universities of Oxford (BMBCh, DM, DSc) and Cambridge (PhD, MD, ScD). His electrophysiological contributions fall in the area of skeletal muscle excitation-contraction coupling, cellular ionic homeostasis and mechanisms for cardiac arrhythmogenesis in genetic models for Na+, K+ and ryanodine receptor channel, and metabolic, abnormality. He is recipient of the Brian Johnson, Rolleston (Oxford) and Gedge Prizes (Cambridge), has been senior editor of the Journal of Physiology, Monographs of the Physiological Society and Biological Reviews, president of the Cambridge Philosophical Society, and served on the British Heart Foundation Advisory Council and Fellowships Committee.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: